Momentum Bioscience on sepsis

Momentum Bioscience is focused on developing rapid tests for patients suspected of sepsis.

Our patented ETGA® technology allows the universal detection of viable organisms in normally sterile samples such as blood. When ETGA® is combined with our innovative, microbial cell and circulating free DNA capture methods, we can provide a rapid, highly sensitive, actionable Gram positive and/or Gram negative and yeast discrimination.

Now incorporated into MagRapid, this test determines presence or absence of viable organisms together with a Gram category from 5mL whole blood in under 3 hr. With a limit of detection of <5 CFU/mL, MagRapid will be able to provide clinically actionable results earlier than blood culture. This will have a significant impact on the management of antibiotics and help mitigate the problem of increasing antimicrobial resistance.

MagRapid is designed to be run on instruments already established in the clinical laboratory and Momentum is seeking partners for joint commercialisation.

 

More about

 

Other news

Upcoming Events

AfPP Residential 2019

York University
8th to the 11th August

Infection Prevention 2019

ACC, Liverpool
22nd - 24th September

IDSc Annual Conference 2019

Jury's Inn, Hinckley Island Hotel
2nd to the 4th December

Latest Issue

Clinical Services Journal

Clinical Services Journal

Jun 2019

VH202 sterilisation: The need for consistency

Register now to apply for regular copies of Clinical Services Journal and free access to premium content, as well as our regular newsletters.

CSJ Supplements

CSJ Supplements

Apr 2019

Putting patients and hospitals first

Register now to apply for regular copies of CSJ Supplements and free access to premium content, as well as our regular newsletters.